You may have seen information in the media recently about the release of NICE guidance (TA1026) Mounjaro (Tirzepatide) injections for managing Obesity and Overweight in Adults, as well as its use to treat Type 2 Diabetes.
From 23rd June 2025 GPs will be able to prescribe Mounjaro on the NHS to certain cohorts of patients that meet strict eligiblity criteria.
A BMI of 40 or higher, or 37.5 or higher if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds AND
At least 4 of the following comorbidities:
- Hypertension and on treatment for blood pressure
- Dyslipidaemia (high cholesterol) or on cholesterol treatment "statins"
- Obstructive Sleep Apnoea
- Cardiovascular disease (Heart conditions, Angina, Stroke)
- Type 2 diabetes
If you feel that you meet the criteria, the first step is to complete an eConsult to provide an up to date height and weight, so that we can calculate your BMI.
We will then check your other conditions (comorbidities) to confirm whether or not you meet the criteria.
If your BMI and comorbidities suggest you may be suitable for Mounjaro, we will then contact you to book an appointment with our HCA.
Please note that you will also be weighed by the practice at this appointment.
You will also be required to engage in a weight management support programme which will be commissioned nationally by NHS England to support patients being prescribed Mounjaro. This is a condition of prescribing set by NHS England.
There are a number of local weight management services currently available for people living with obesity or overweight, and we are happy to discuss these and support you with your weight management goals.